TEV-48125 for the preventive treatment of chronic migraine

Abstract

Objective:To evaluate the onset of efficacy of TEV-48125, a monoclonal antibody against calcitonin gene-related peptide, recently shown to be effective for the preventive treatment of chronic migraine (CM) and high-frequency episodic migraine.Methods:A randomized placebo-controlled study tested once-monthly injections of TEV-48125 675/225 mg or 900 mg vs placebo. Headache information was captured daily using an electronic headache diary. The primary endpoint was change from baseline in the number of headache hours in month 3. Herein, we assess the efficacy of each dose at earlier time points.Results:The sample consisted of 261 patients. For headache hours, the 675/225-mg dose separated from placebo on day 7 and the 900-mg dose separated from placebo after 3 days of therapy (p = 0.048 and p = 0.033, respectively). For both the 675/225-mg and 900-mg doses, the improvement was sustained through the second (p = 0.004 and p < 0.001) and third (p = 0.025 and p < 0.001) weeks of therapy and throughout the study (month 3, p = 0.0386 and p = 0.0057). For change in weekly headache days of at least moderate intensity, both doses were superior to placebo at week 2 (p = 0.031 and p = 0.005).Conclusions:TEV-48125 demonstrated a significant improvement within 1 week of therapy initiation in patients with CM.Classification of evidence:This study provides Class II evidence that for patients with CM, TEV-48125 significantly decreases the number of headache hours within 3 to 7 days of injection.

History and Review of anti‐Calcitonin Gene‐Related Peptide (CGRP) Therapies: From Translational Research to Treatment

“…As noted above, this trial had 2 active arms, In one arm, the first dose was 675 mg, followed by 2 doses of 225 mg in monthly subcutaneous injections for 12 weeks. In the second arm, patients received 900 mg monthly for the 3 months …”

Greater Occipital Nerve Injection versus Oral Steroids for Short Term Prophylaxis of Cluster Headache: A Retrospective Comparative Study

“…17 Novel CH treatment modalities, such as implanted sphenopalatine ganglion nerve stimulation 18 and vagal nerve stimulation [19][20][21] that are potentially effective for both acute and preventative therapy could have diminished treatment latencies and replace the need for distinctive transitional therapies. 22 Ideally, a future study addressing transitional therapy for CH would be a prospective, randomized, placebo/sham controlled clinical trial to better ascertain the optimal dosage and length of treatment for oral prednisone compared to GON steroid injection for transitional treatment of CH. 22 Ideally, a future study addressing transitional therapy for CH would be a prospective, randomized, placebo/sham controlled clinical trial to better ascertain the optimal dosage and length of treatment for oral prednisone compared to GON steroid injection for transitional treatment of CH.…”

Fremanezumab as Add‐On Treatment for Patients Treated With Other Migraine Preventive Medicines

“…Eligible patients (aged 18‐65 years) were individuals with migraine happening on at least 8 days per month but with headaches on no more than 14 days per month (EM study) or with CM as per the International Classification of Headache Disorders (ICHD 3rd edition, beta version) and details of the trials have been described elsewhere . During the EM and CM studies, at the discretion of their doctor, patients could be on preventive drugs, used according to the recommended migraine dose and for a proper duration (at least 3 months of consecutive use).…”